Adaptimmune Therapeutics Plc (ADAP NASDAQ) stock market data APIs
$0.0805
-0(-0%)
as of September 17, 2025
Try our APIs with
free plan!
Adaptimmune Therapeutics Plc Financial Data Overview
Price chart is built with
Anychart
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Prev. Close
0.0805
Open
0.0793
High
0.0857
Low
0.0737
52 wk Range
0.0403-1.06
Market Cap
21 681 K
Shares Outstanding
265 M
Revenue
65 085 K
EPS
-0.02
Beta
2.241
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adaptimmune Therapeutics Plc data using free add-ons & libraries
Get Adaptimmune Therapeutics Plc Fundamental Data
Adaptimmune Therapeutics Plc Fundamental data includes:
- Net Revenue: 65 085 K
- EBITDA: -137 240 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adaptimmune Therapeutics Plc News
New
Discover the most active stocks in Tuesday's session.
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session. [mostactive] TODAY'S MOST ACTIVE STOCKS TICKER CHANGE COMME...
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT FGI [https://www.chartmill...
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. [gap] TOD...
Biotech And Medtech Stocks Rally After-Hours Across Key Names
(RTTNews) - On September 12, several healthcare and biotech stocks experienced a surge in after-hours trading, marked by sharp price movements across the sector. From thrombectomy devices to AI-powere...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
